GOODRX HOLDINGS INC. CL.A

At the GoodRx annual meeting, shareholders voted to elect class‑III directors Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre and to appoint KPMG as independent auditors for fiscal year 2026. In a non‑binding vote, shareholders also approved the performance‑based compensation for the named executives. GoodRx reported Q1 2026 EPS of $0.07 (plan met) and revenue of $194 million (4.7% above expectations) and introduced a monthly subscription offering, "GoodRx Companion," for $14.99. » More on de.investing.com

GoodRx introduced Companion, a $14.99/month subscription aimed at patients with chronic conditions that combines savings on more than 200 common generic medications with discounted dental services and $19 telehealth visits for routine issues. The service expands GoodRx’s subscription strategy and creates a more predictable recurring revenue stream by engaging consumers beyond one-off prescription transactions. Companion also offers lower-cost access to exams, cleanings, X-rays and other dental care. » More on finance.yahoo.com

GoodRx reported Q1 2026 earnings per share of $0.07 (in line with expectations) and revenue of $194 million, beating the forecast by 4.71%. The stock rose 10.94% in after-hours trading; in premarket trading it fell 2.82%. The company raised its full-year revenue guidance to $765–785 million and sees growth in Pharma Direct and subscriptions, while revenue from prescription transactions declined 24%. » More on de.investing.com